<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343367">
  <stage>Registered</stage>
  <submitdate>22/08/2011</submitdate>
  <approvaldate>22/08/2011</approvaldate>
  <actrnumber>ACTRN12611000895987</actrnumber>
  <trial_identification>
    <studytitle>A Non-Therapeutic study to assess the Functionality of the Kona Renal Denervation System in Subjects Undergoing Diagnostic Angiography</studytitle>
    <scientifictitle>A Non-Therapeutic Feasibility Pilot Study to Assess the Targeting and Tracking Functionality of the Kona Renal Denervation System in Subjects Undergoing Diagnostic Angiography</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypertension</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The Kona Renal Denervation System (RDS) is a focused therapeutic ultrasound system designed to administer catheter-guided, focused therapeutic ultrasound treatments to the sympathetic nerve complex of the renal artery to induce renal neurolysis (i.e., coagulation of the sympathetic nerves that innervate the kidneys).  This Pilot study is intented to test the targeting and tracking function of the device only.   The therapy (dosing) system components will be disabled in this pilot study.  This research study will add between 15 to 30 minutes to the scheduled diagnostic angiography.</interventions>
    <comparator>Nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Assess the device-patient interface and renal artery targeting and tracking capability of the Kona Renal Denervation System (RDS) in patients who are undergoing diagnostic angiography via ultrasound</outcome>
      <timepoint>The ultrasound takes approximatley 5 minutes, and will occur after the routine angiography, just after the insertion of the Kona targeting catherter.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>a.	Subject is at least 18 years of age.
b.	Subject is scheduled to undergo elective, diagnostic angiography.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>a.	Subject has a body weight &gt; 150 kilograms.
b.	Subject is pregnant, nursing or intends to become pregnant during the trial period.
c.	Subject is currently enrolled in other potentially confounding research.
d.	Subject has any condition that, at the discretion of the investigator, would preclude participation in the trial.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Educational / counselling / training</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/10/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pacific Clinical Research Group</primarysponsorname>
    <primarysponsoraddress>Suite G03, 1 Cassins Ave
North Sydney, NSW 2060</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>KONA Medical Inc.</fundingname>
      <fundingaddress>2495 140th Ave NE, Suite D100
Bellevue, WA 98005</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to research one aspect, the non-therapeutic targeting and tracking functionality, of the Kona Renal Denervation System. The research project is being conducted to gather information about how the system functions when placed in a clinical setting.  Information gathered from this research project will be used for the development of the Kona Renal Denervation System.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincent's Hospital (Melbourne) HREC-D</ethicname>
      <ethicaddress>PO Box 2900
Fitzroy VIC 3065</ethicaddress>
      <ethicapprovaldate />
      <hrec>1/11/0101</hrec>
      <ethicsubmitdate>10/08/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Thomas Anderson</name>
      <address>Kona Medical Inc.
2495 140th Ave NE, Suite D100
Bellevue, WA 98005</address>
      <phone>+1 425 558 4616</phone>
      <fax />
      <email>tanderson@konamedical.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Anna Calleja</name>
      <address>Project Manager
PO Box 1600
North Sydney NSW 2059</address>
      <phone>+61 02 9925 4210</phone>
      <fax />
      <email>anna.calleja@pcrg.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Anna Calleja</name>
      <address>PO Box 1600
North Sydney NSW 2059</address>
      <phone>+61 02 9925 4210</phone>
      <fax />
      <email>anna.calleja@pcrg.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>